On March 5, GLONGHUI (01846.HK) announced that the Group is expected to record: (i) profit attributable to the owners of the company ranged from about HK$128 million to HK$135 million, compared with about HK$89.5 million last year; and (ii) profit before interest, tax, depreciation and amortization for the year was approximately HK$278 million to HK$290 million, an increase of about 30% to 36% over the previous year's approximately HK$214 million.
The Board believes that compared to last year, the expected increase in profit and profit before interest, tax, depreciation and amortization due to (i) the strong recovery of China's economic and market conditions after COVID-19 restrictions were lifted, leading to an increase in the total number of ophthalmic surgeries performed by the Group; (ii) increased demand for presbyopia surgery, which led to an increase in profit contribution; and (iii) the Group remained resilient in the face of a challenging economic environment due to the strong increase in the total number of eye surgeries performed by the Group in Europe.